|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 31/56 | (2006.01) |
| (11) | Number of the document | 1734970 |
| (13) | Kind of document | T |
| (96) | European patent application number | 05729394.6 |
| Date of filing the European patent application | 2005-03-14 | |
| (97) | Date of publication of the European application | 2006-12-27 |
| (45) | Date of publication and mention of the grant of the patent | 2014-12-31 |
| (46) | Date of publication of the claims translation | 2015-04-27 |
| (86) | Number | PCT/US2005/008575 |
| Date | 2005-03-14 |
| (87) | Number | WO 2005/089316 |
| Date | 2005-09-29 |
| (30) | Number | Date | Country code |
| 552865 P | 2004-03-12 | US |
| (72) |
FIORUCCI, Stefano, IT
PELLICCIARI, Roberto, IT
PRUZANSKI, Mark, US
|
| (73) |
Intercept Pharmaceuticals, Inc.,
421 Hudson Street, Suite 212, New York, NY 10014,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Fibrozės gydymas, panaudojant FXR ligandus |
| TREATMENT OF FIBROSIS USING FXR LIGANDS |
| Payment date | Validity (years) | Amount | |
| 2023-02-20 | 19 | 347.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-03-14 |